SCHEDULE: Federated Hermes Discloses 6.68% Beneficial Ownership in EyePoint Pharmaceuticals

Federated Hermes, Inc. and affiliated entities have disclosed a 6.68% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., held in the ordinary course of business.

Summary

• Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust and its trustees (Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue), collectively reported beneficial ownership of 4,599,450 shares of EyePoint Pharmaceuticals, Inc. common stock.
• This aggregate amount represents 6.68% of the class of securities.
• Federated Hermes, Inc. and the Voting Shares Irrevocable Trust each hold sole voting and sole dispositive power over all 4,599,450 shares.
• Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each hold shared voting and shared dispositive power over all 4,599,450 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of EyePoint Pharmaceuticals, Inc., nor in connection with any transaction having such purpose or effect, other than activities solely related to a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects. It is a factual report of ownership.

Positives

• The significant ownership stake by a major investment manager like Federated Hermes, Inc. may signal institutional confidence in EyePoint Pharmaceuticals, Inc.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a stable, passive investment.

Risks

• The reporting persons, including Federated Hermes, Inc., the Voting Shares Irrevocable Trust, and the individual trustees, expressly disclaim beneficial ownership of the reported securities, which is a legal nuance common in such filings where ownership is indirect through managed funds.

Future Outlook

NA

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

EyePoint Pharmaceuticals, Inc. operates in the pharmaceutical industry. This filing indicates a significant passive investment by Federated Hermes, Inc., a prominent global investment manager, in a company within this sector.

Related Party Transactions

• Federated Hermes, Inc. is the parent holding company of several investment advisers (Federated Global Investment Management Corp., Federated Investment Counseling, Federated MDTA LLC) that manage registered investment companies and separate accounts owning shares of EyePoint Pharmaceuticals, Inc.
• All of Federated Hermes, Inc.'s outstanding voting stock is held in the Voting Shares Irrevocable Trust.
• Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue act as trustees for the Voting Shares Irrevocable Trust and have joined in filing this Schedule 13G due to their collective voting control over Federated Hermes, Inc.

Stakeholder Impact

• Shareholders of EyePoint Pharmaceuticals, Inc. are informed of a significant institutional ownership stake, which can influence market perception and liquidity.

Key Dates

Keywords

EyePoint Pharmaceuticals, Federated Hermes, Beneficial Ownership, Schedule 13G, Common Stock, Investment Management, Pharmaceuticals, Institutional Investor